Early Notification of one funded brand of Lamotrigine Dispersible Tablets
Not so early notification in reality – we received our notification from PHARMAC at 3.02pm on the 11th April 2019.
As advised via PHARMAC proposal of 29 August 2018 and the notification of PHARMAC decision of 11 April 2019 there is to be a change in the listing and future sole supply of lamotrigine dispersible tablets 25mg, 50 mg and 100 mg.
New listing from 1 May 2019 (price & subsidy decrease only)
Logem Tab dispersible 25 mg 56 Pharmacode 2553376 Schedule price from $19.38 to $2.76
Logem Tab dispersible 50 mg 56 Pharmacode 2553384 Schedule price from $32.97 to $3.31
Logem Tab dispersible 100 mg 56 Pharmacode 2553392 Schedule price from $56.91 to $4.40
Incumbent brand (all delisting 1 October 2019)
Lamictal Tab dispersible 25 mg 56 Pharmacode 417866 Schedule price $29.09
Lamotrigine-Arrow Tab dispersible 25 mg 56 Pharmacode 2245515 Schedule price $20.40
Lamictal Tab dispersible 50 mg 56 Pharmacode 418021 Schedule price $47.89
Lamotrigine-Arrow Tab dispersible 50 mg 56 Pharmacode 2245507 Schedule price $34.70
Lamictal Tab dispersible 100 mg 56 Pharmacode 418498 Schedule price $79.16
Lamotrigine-Arrow Tab dispersible 100 mg 56 Pharmacode 2245493 Schedule price $59.90
Reference pricing will not apply.
Instead there will be a 5 month transition period from 1 May 2019 to 30 September 2019 where incumbent brands will remain listed and funded at existing schedule pricing.
HSS (Hospital Supply Status) & CSS (Community Supply Status) commences 1 October 2019.
Brand switch fee will apply from 1 October 2019 to 1 January 2020.
As of the date of this notification ProPharma / PWR cannot accept Lamictal or Lamotrigine-Arrow for credit under any circumstances.
From 1 May 2019 community pharmacies dispensing lamotrigine will need to support patients changing to Logem brand and manage stock during the transition.
We would recommend you continue to purchase the incumbent.
Due to the new Logem 25mg & 50 mg pricing (both Low Cost Medicines) we will be unable to set automatic replacements for those strengths. We will however set up automatic replacement for the 100mg as stocks of the incumbent 2 brands are exhausted.
You MUST manage your stock to avoid being caught with stock at the time sole supply commences 1 October 2019. Failure to do so may prove very costly.
Once again we need your support to ensure stock in the supply chain moves through, to effectively ensure no losses are incurred by – supplier, wholesaler and pharmacy.
ProPharma / PWR will make a commercial decision in relation to stock holding which will potentially mean a change for pharmacy and patient. Unfortunately with the PHARMAC decision to have all three products listed and fully funded until the commencement of the sole supply we need to act in the best interest of the company, pharmacy and patient. The patient will need to change, however wholesalers and pharmacy do not need to experience potential losses during the transition period.
Together we can make this a seamless and painless transition.
We thank you in anticipation of your ongoing support.